Nyxoah (NASDAQ:NYXH) Posts Earnings Results, Misses Expectations By $0.04 EPS

Nyxoah (NASDAQ:NYXH) announced its quarterly earnings data on Thursday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04), FiscalAI reports. The company had revenue of $6.62 million for the quarter, compared to the consensus estimate of $5.70 million. Nyxoah had a negative return on equity of 101.99% and a negative net margin of 1,457.97%.

Here are the key takeaways from Nyxoah’s conference call:

• The company received FDA approval for Genio in August 2025, secured Medicare and broad commercial reimbursement, and quickly generated U.S. revenue (about $4.5M in Q4) contributing to EUR 11M global gross revenue and ~EUR 10M net revenue for 2025 with ~63–64% gross margin.
• Commercial execution accelerated: 145 surgeons trained across ~125 targeted accounts, 120 Value Analysis Committee submissions with 57 approvals, and the U.S. sales force expanded from 25 to 40 reps now covering ~200 of the top 400 accounts.
• Clinical and regulatory catalysts are in progress — the DREAM pivotal study was published showing efficacy in supine and non‑supine positions, and 12‑month ACCCESS data are expected by end‑June 2026 to support a PMA supplement and potential U.S. label expansion in early 2027.
• Profitability and cash runway remain challenges: 2025 operating loss widened to EUR 83.5M, cash totaled EUR 48M at year‑end, management estimates ~EUR 20M quarterly cash burn and says current funding supports operations into Q1 2027 absent faster revenue ramp or additional financing.

Nyxoah Stock Performance

NASDAQ:NYXH traded up $0.03 on Thursday, hitting $3.09. The company’s stock had a trading volume of 19,062 shares, compared to its average volume of 50,584. Nyxoah has a one year low of $3.05 and a one year high of $11.87. The firm has a market capitalization of $105.25 million, a P/E ratio of -1.24 and a beta of 1.56. The stock has a fifty day moving average of $4.41 and a two-hundred day moving average of $4.88. The company has a current ratio of 1.70, a quick ratio of 1.41 and a debt-to-equity ratio of 0.40.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NYXH shares. Cantor Fitzgerald upgraded shares of Nyxoah to a “strong-buy” rating in a report on Wednesday, March 4th. Stifel Nicolaus cut their price target on shares of Nyxoah from $12.00 to $11.00 and set a “buy” rating for the company in a research note on Thursday, January 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Nyxoah in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Heights Capital Management Inc. bought a new stake in Nyxoah in the 4th quarter valued at $3,575,000. Shay Capital LLC bought a new position in Nyxoah during the second quarter worth $374,000. Deutsche Bank AG boosted its position in Nyxoah by 40.0% during the fourth quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock worth $161,000 after purchasing an additional 10,000 shares during the period. Citadel Advisors LLC acquired a new position in shares of Nyxoah in the third quarter valued at $98,000. Finally, Bank of America Corp DE increased its holdings in shares of Nyxoah by 152.7% in the third quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock valued at $91,000 after purchasing an additional 12,012 shares during the last quarter.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.